Norah Terrault, MD
Transplant Hepatology · Los Angeles, CANPI 1225086283
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 74.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $6,935 and has fallen 98.2% since, to $125 in 2025.
Across 7 payments — averaging $1864.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$10K
- Intercept Pharmaceuticals, Inc.$3K
- GSK$175
- AbbVie$35
Across 138 payments — averaging $14,074 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.4M
- GSK$256K
- AbbVie$114K
- Hoffmann-la Roche Limited$65K
- Eiger Biopharmaceuticals, Inc.$62K
- Genentech, Inc.$32K
- plus $22K from 3 others
What the payments were for
- Consulting fees$2,71021%
- Speaking & faculty fees$3,12024%
- Travel & lodging$6,90053%
- Food & beverage$3232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $9,723 |
| Intercept Pharmaceuticals, Inc. | 1 | $3,120 |
| GSK | 2 | $175 |
| AbbVie | 1 | $35 |
How this compares
$13,053 in reported general payments places this provider in the 70th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 19 | $61,581 |
| Ursodiol | 12 | $1,309 |
| Entecavir | 12 | $440 |
| Carvedilol | 48 | $149 |
| Spironolactone | 22 | $148 |
| Klor-Con 10Potassium Chloride | 13 | $5 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in Los Angeles
- Julio GutierrezLos Angeles$895K
- Pei Lim LeeLos Angeles$79K
- Beshoy YannyLos Angeles$50K
- Kali ZhouLos Angeles$50K
- Jasleen SinghLos Angeles$46K
- Jeffrey KahnLos Angeles$9K
- Brian KimLos Angeles$7K
- Tse Ling FongLos Angeles$6K
- Liyun YuanLos Angeles$4K
- Cynthia CherfaneLos Angeles$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.